Cargando…

Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center

BACKGROUND: Lymphoplasma exchange (LPE), a technique combining plasma exchange with leukapheresis, is emerging as promising treatment for autoimmune diseases. Data on the efficacy and safety of LPE in myasthenia gravis (MG) therapy are scarce. In this study, we aimed to comprehensively review the cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouyang, Song, Yin, Weifan, Zeng, Qiuming, Li, Bijuan, Zhang, Jian, Duan, Weiwei, Li, Yi, Liang, Yong, Wang, Jiaqi, Tan, Hong, Yang, Huan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063637/ https://www.ncbi.nlm.nih.gov/pubmed/35514988 http://dx.doi.org/10.3389/fimmu.2022.757841

Ejemplares similares

Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study
por: Duan, Weiwei, et al.
Publicado: (2023)

Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis
por: Duan, Weiwei, et al.
Publicado: (2022)

To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis
por: Zhou, Qian, et al.
Publicado: (2021)

Inflammation and autoimmune myasthenia gravis
por: Huda, Ruksana
Publicado: (2023)

Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis
por: Bi, Zhuajin, et al.
Publicado: (2023)

Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis
por: Wang, Shumin, et al.
Publicado: (2021)

Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
por: Wang, Zhen, et al.
Publicado: (2017)

Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)

Muscle-Specific Kinase Myasthenia Gravis
por: Borges, Lucia S., et al.
Publicado: (2020)

Editorial: Advances in Autoimmune Myasthenia Gravis
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis
por: Duan, Weiwei, et al.
Publicado: (2021)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Therapeutic plasma exchange in the treatment of myasthenia gravis
por: Kumar, Rajesh, et al.
Publicado: (2015)

Role of miRNAs in Normal and Myasthenia Gravis Thymus
por: Cron, Mélanie A., et al.
Publicado: (2020)

The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis
por: Seok, Hung Youl, et al.
Publicado: (2017)

Outcome of therapeutic plasma exchange in Myasthenia gravis patients
por: Dogra, Ashu, et al.
Publicado: (2020)

Soluble glucocorticoid-induced tumor necrosis factor receptor regulates Helios expression in myasthenia gravis
por: Li, Yi, et al.
Publicado: (2019)

Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)

Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)

Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis
por: Gable, Karissa L., et al.
Publicado: (2020)

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)

New Approaches to Targeting B Cells for Myasthenia Gravis Therapy
por: Huda, Ruksana
Publicado: (2020)

Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases
por: Zhu, Ying, et al.
Publicado: (2023)

Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
por: Luo, Yue-Bei, et al.
Publicado: (2021)

Clinical Evaluation of the Efficacy and Safety of Co-Administration of Wuzhi Capsule and Tacrolimus in Adult Chinese Patients with Myasthenia Gravis
por: Peng, Yuyao, et al.
Publicado: (2021)

Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis
por: Díez-Porras, Laura, et al.
Publicado: (2020)

An Interesting Case Report of Myasthenia Gravis Exacerbation Induced by Durvalumab
por: Abidoye, Oluseyi, et al.
Publicado: (2022)

Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis
por: Ruan, Zhe, et al.
Publicado: (2022)

The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
por: Peng, Siyang, et al.
Publicado: (2022)

Herpesvirus entry mediator on T cells as a protective factor for myasthenia gravis: A Mendelian randomization study
por: Zhong, Huahua, et al.
Publicado: (2022)

Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study
por: Ruan, Zhe, et al.
Publicado: (2023)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

Immunotherapy choice and maintenance for generalized myasthenia gravis in China
por: Zhang, Chao, et al.
Publicado: (2020)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis
por: Cron, Mélanie A., et al.
Publicado: (2019)

Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology
por: Fichtner, Miriam L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i9cjnbofm2l1rn03abce9vopg1